Amneal Pharmaceuticals Wins FDA Approval for Generic Albuterol Inhaler

+0.43%

Amneal Pharmaceuticals, Inc. Class A

AMRX

12.93

+0.43%

Amneal Pharmaceuticals Inc. has received U.S. Food and Drug Administration (FDA) approval for its albuterol sulfate inhalation aerosol (90 mcg per actuation), the generic equivalent of PROAIR® HFA. This marks Amneal's second complex respiratory therapeutic product approval in the fourth quarter of 2025, following the recent FDA approval of its beclomethasone dipropionate inhalation aerosol, a generic equivalent of QVAR®. These approvals strengthen Amneal's presence in the respiratory drug delivery market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594778-en) on December 02, 2025, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.